Prashanth Gopalakrishna

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: January 28, 2026

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 17, 2018

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Journal: Journal of cancer research and clinical oncology

Published: January 22, 2018

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Journal: Journal of hematology & oncology

Published: August 08, 2017

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Journal: Leukemia

Published: March 02, 2017

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Journal: Haematologica

Published: September 03, 2016

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Journal: Leukemia

Published: March 10, 2016

Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

Journal: Leukemia & lymphoma

Published: February 27, 2016

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Journal: British journal of haematology

Published: August 26, 2015

JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib.

JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib.

Journal: Annals of hematology

Published: July 12, 2015

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

Journal: Experimental hematology & oncology

Published: May 26, 2015

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Journal: Haematologica

Published: October 28, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026